DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 886 filers reported holding DANAHER CORPORATION in Q3 2014. The put-call ratio across all filers is 0.41 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,057,163,987 | +4.3% | 7,750,599 | +1.5% | 0.50% | -5.3% |
| Q3 2022 | $1,972,355,906 | +1.7% | 7,636,207 | -0.1% | 0.52% | +4.6% |
| Q2 2022 | $1,938,519,891 | +1.3% | 7,646,418 | +17.2% | 0.50% | +20.1% |
| Q1 2022 | $1,913,772,919 | -5.1% | 6,524,300 | +6.5% | 0.42% | +0.7% |
| Q4 2021 | $2,015,889,000 | +8.5% | 6,127,135 | +0.4% | 0.41% | +0.7% |
| Q3 2021 | $1,858,810,000 | +6.1% | 6,105,670 | -6.5% | 0.41% | +8.2% |
| Q2 2021 | $1,752,512,000 | +14.2% | 6,530,450 | -4.2% | 0.38% | +8.3% |
| Q1 2021 | $1,534,723,000 | -6.0% | 6,818,568 | -7.3% | 0.35% | -7.9% |
| Q4 2020 | $1,633,545,000 | +1.2% | 7,353,674 | -1.9% | 0.38% | -11.2% |
| Q3 2020 | $1,614,419,000 | +28.1% | 7,497,417 | +5.2% | 0.43% | +18.2% |
| Q2 2020 | $1,260,437,000 | +26.6% | 7,127,958 | -0.9% | 0.36% | +2.3% |
| Q1 2020 | $995,974,000 | -9.1% | 7,195,827 | +0.8% | 0.36% | +16.0% |
| Q4 2019 | $1,095,974,000 | +5.5% | 7,140,825 | -0.8% | 0.31% | -3.8% |
| Q3 2019 | $1,039,280,000 | +0.2% | 7,195,733 | -0.9% | 0.32% | -0.9% |
| Q2 2019 | $1,037,688,000 | +7.3% | 7,260,616 | -0.9% | 0.32% | +2.9% |
| Q1 2019 | $967,064,000 | +29.4% | 7,325,132 | +1.1% | 0.31% | +12.2% |
| Q4 2018 | $747,082,000 | -2.5% | 7,244,784 | +2.7% | 0.28% | +11.6% |
| Q3 2018 | $766,162,000 | +13.9% | 7,051,006 | +3.4% | 0.25% | +7.8% |
| Q2 2018 | $672,774,000 | +4.0% | 6,817,740 | +3.2% | 0.23% | -1.3% |
| Q1 2018 | $647,079,000 | +0.9% | 6,608,908 | -4.3% | 0.23% | +1.7% |
| Q4 2017 | $641,065,000 | +8.2% | 6,906,545 | 0.0% | 0.23% | +2.2% |
| Q3 2017 | $592,443,000 | +6.7% | 6,906,545 | +5.0% | 0.22% | +2.3% |
| Q2 2017 | $554,997,000 | +2.7% | 6,576,583 | +4.1% | 0.22% | -0.9% |
| Q1 2017 | $540,226,000 | +16.1% | 6,316,215 | +5.6% | 0.22% | +9.4% |
| Q4 2016 | $465,363,000 | +5.8% | 5,978,443 | +1.7% | 0.20% | -2.4% |
| Q3 2016 | $439,948,000 | -19.9% | 5,876,076 | +8.1% | 0.21% | -20.3% |
| Q2 2016 | $549,054,000 | +0.5% | 5,436,179 | -5.6% | 0.26% | -3.0% |
| Q1 2016 | $546,489,000 | -3.5% | 5,761,007 | -5.5% | 0.27% | -4.3% |
| Q4 2015 | $566,144,000 | +9.6% | 6,095,437 | +0.5% | 0.28% | +3.7% |
| Q3 2015 | $516,630,000 | -10.7% | 6,063,021 | -10.3% | 0.27% | -6.2% |
| Q2 2015 | $578,797,000 | -4.1% | 6,762,425 | -4.9% | 0.29% | -2.4% |
| Q1 2015 | $603,590,000 | +3.3% | 7,109,425 | +4.3% | 0.30% | -0.3% |
| Q4 2014 | $584,187,000 | +15.0% | 6,815,851 | +2.0% | 0.30% | +8.0% |
| Q3 2014 | $507,957,000 | -53.4% | 6,685,401 | -51.7% | 0.28% | -6.5% |
| Q2 2014 | $1,090,008,000 | +87.5% | 13,844,878 | +78.6% | 0.29% | -10.4% |
| Q1 2014 | $581,307,000 | -9.8% | 7,750,759 | -7.2% | 0.33% | -11.6% |
| Q4 2013 | $644,614,000 | +6.4% | 8,349,929 | -4.4% | 0.37% | +5.1% |
| Q3 2013 | $605,702,000 | +15.1% | 8,737,772 | +5.1% | 0.35% | +8.0% |
| Q2 2013 | $526,390,000 | +40.5% | 8,315,796 | +37.9% | 0.33% | +34.6% |
| Q1 2013 | $374,668,000 | +30.6% | 6,028,450 | +15.9% | 0.24% | +25.9% |
| Q3 2012 | $286,816,000 | +5.5% | 5,200,660 | +1.0% | 0.19% | -11.5% |
| Q2 2012 | $271,949,000 | – | 5,149,584 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |